The neurofibromatoses: When less is more

Human Molecular Genetics

Volumn 10, Issue 7, 2001, Pages 747-755

  Gutmann, David H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8111 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; MERLIN; NEUROFIBROMIN; PROTEIN P21; RAS PROTEIN;

CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SWITCHING; GENETIC CODE; HUMAN; MITOGENESIS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

FALCO COLUMBARIUS;

EID: 0035057829     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/10.7.747     Document Type: Review

References (86)

1. Mutation and cancer: Statistical study of retinoblastoma
2. Neurofibromatosis: Past, present and future
3. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study
4. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 optic pathway glioma task force
5. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
6. A major segment of the neurofibromatosis type 1 gene: CDNA sequence, genomic structure and point mutations
7. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients
8. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S.cerevisiae
9. The neurofibromatosis type 1 gene encodes a protein related to GAP
10. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
11. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
12. Loss of neurofibromin is associated with activation of ras/MAPK and PIS-K/akt signaling in a neurofibromatosis 1 astrocytoma
13. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
14. Single cell Ras-GTP analysis reveals altered ras activity in a single population of neurofibroma Schwann cells but not fibroblasts
15. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
16. Aberrant regulation of ras proteins in tumour cells from type 1 neurofibromatosis patients
17. ras contributes to malignant tumor growth in on Recklinghausen (type 1) neurofibromatosis
18. Neurofibromin GAP related domains (GRDs) restore normal growth in Nf1-/- cells
19. Tumor predisposition in mice heterozygous for a targeted mutation in NF1
20. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues
21. Mouse models of tumor development in neurofibromatosis type 1
22. Chromosome 17p deletions and p53 gene mutation associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis
23. Mouse tumor model for neurofibromatosis type 1
24. Nfl;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
25. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas
26. Cancer-related gene expression in neurofibromatosis 1 (NF1)-associated pilocytic astrocytomas
27. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains
28. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation
29. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes
30. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo
31. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides
32. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A
33. NF1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farsenyl protein transferase
34. An alternatively spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle
35. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues
36. Expression of a developmentally regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene
37. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform
38. A clinical study of type 2 neurofibromatosis
39. A noel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor
40. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2
41. ERM family: From cytoskeleton to signal transduction
42. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells
43. The Nf2 tumor suppressor gene product is essential for extra-embryonic development immediately prior to gastrulation
44. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein
45. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization
46. The neurofibromatosis-2 homologue, merlin and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation
47. Neurofibromatosis 2 tumor suppressor protein co-localizes with ezrin and CD44 and associates with actin-containing cytoskeleton
48. CD44 acts as both a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor
49. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44
50. Merlin differentially associates with the microtubule and actin cytoskeleton
51. The neurofibromatosis 2 gene product schwannomin interacts with beta-II-spectrin
52. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins
53. The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate
54. NHE-RF, a regulatory cofactor for Na+-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins
55. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF
56. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family
57. Merlin, the neurofibromatosis type 2 gene product and beta-1 integrin associate in isolated and differentiating Schwann cells
58. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors
59. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human schwannoma cells
60. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading
61. Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression
62. The CD44 receptor of lymphoma cells: Structure-function relationships and mechanism of activation
63. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts
64. Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations
65. Interdomain binding mediates tumor growth suppression by the NF2 gene product
66. Defects in neurofibromatosis 2 protein function can arise at multiple levels
67. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain
68. Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a structurally conserved putative zinc finger domain
69. Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor
70. Hrs, a FYE finger protein localized to early endosomes, is implicated in vesicular traffic and required for ventral folding morphogenesis
71. Hrs is associated with STAM, a signal-transducing adaptor molecule
72. Hgs (Hrs), a FYVE domain protein, is involved in smad signaling through cooperation with SARA
73. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas
74. The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility
75. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
76. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
77. Universal absence of merlin, but not other ERM family members, in schwannomas
78. Reduced expression of schwannomin/merlin in human sporadic meningiomas
79. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
80. The neurofibromatosis type 2 gene is inactivated in schwannomas
81. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2
82. Merlin, DAL-1 and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemistry study of 175 cases
83. A novel member of the NF2/ERM/4.1 superfamily with growth suppressor properties in lung cancer
84. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas
85. The Protein 4.1 tumor suppressor, DAL-1 impairs cell motility, but regulates proliferation in a cell type-specific fashion